Dow Crosses 16,000 Despite Merck's Fall
Merck and Big Pharma have had a slow day, but a strong showing from financials and industrials helped the Dow soar to new heights.
Has Myeloma Met Its Match in Amgen's Kyprolis?
Amgen's high profile acquisition of Onyx Pharmaceuticals gave it Kyprolis, an existing multiple myeloma treatment with an opportunity to expand beyond its current indication.
What the End of Bristol-Myers Squibb Royalties Means for Repligen
Repligen stands to lose all of its royalties on Orencia from Bristol-Myers Squibb in 2014. Here's what investors need to know.